Enhancing neuronal function and repair by restoring functional inhibition to treat CNS diseases.

Axonis Therapeutics is developing a platform of first-in-class therapies that target KCC2, a critical mediator of inhibition in the central nervous system. Potentiating KCC2 activity restores functional inhibition and restores the inhibition/excitation balance that is dysfunctional in epilepsy, pain and other CNS pathologies.